Our top pick for
Building a portfolio
Assertio Holdings, Inc is a drug manufacturers-specialty & generic business based in the US. Assertio shares (ASRT) are listed on the NASDAQ and all prices are listed in US Dollars. Assertio employs 27 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$0.33 - $1.45|
|50-day moving average||$0.81|
|200-day moving average||$0.66|
|Wall St. target price||$1.55|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.06|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Assertio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Assertio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Assertio's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $14 million.
The EBITDA is a measure of a Assertio's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$108.1 million|
|Gross profit TTM||$92.3 million|
|Return on assets TTM||-6.43%|
|Return on equity TTM||-49.61%|
|Market capitalisation||$96 million|
TTM: trailing 12 months
There are currently 3.8 million Assertio shares held short by investors – that's known as Assertio's "short interest". This figure is 13.2% down from 4.4 million last month.
There are a few different ways that this level of interest in shorting Assertio shares can be evaluated.
Assertio's "short interest ratio" (SIR) is the quantity of Assertio shares currently shorted divided by the average quantity of Assertio shares traded daily (recently around 10.8 million). Assertio's SIR currently stands at 0.35. In other words for every 100,000 Assertio shares traded daily on the market, roughly 350 shares are currently held short.
However Assertio's short interest can also be evaluated against the total number of Assertio shares, or, against the total number of tradable Assertio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Assertio's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Assertio shares in existence, roughly 20 shares are currently held short) or 0.022% of the tradable shares (for every 100,000 tradable Assertio shares, roughly 22 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Assertio.
Find out more about how you can short Assertio stock.
We're not expecting Assertio to pay a dividend over the next 12 months.
Over the last 12 months, Assertio's shares have ranged in value from as little as $0.33 up to $1.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Assertio's is 1.5758. This would suggest that Assertio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Assertio Holdings, Inc. , a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company's pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, an NSAID for relief of mild to moderate acute pain; and SPRIX, an NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.